Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells
Tóm tắt
The current study was carried out to identify the JAK molecule(s) that is involved in the IL-13-induced activation of STAT6 in cultured human bronchial smooth muscle cells (hBSMCs). Cultured hBSMCs were stimulated with IL-13 in the absence and presence of JAK inhibitor-I (a nonspecific JAKs inhibitor), tyrphostin-AG490 (a specific JAK2 inhibitor), WHI-P131 (a specific JAK3 inhibitor), or tyrphostin-AG9 (a specific Tyk2 inhibitor), and levels of phosphorylated STAT6 were measured by immunoblot analyses. The IL-13-induced phosphorylation of STAT6 was abolished by JAK inhibitor-I, whereas the other inhibitors had no significant effect. These findings indicate that the STAT6 phosphorylation/activation induced by IL-13 is mediated by an activation of JAK1 in cultured hBSMCs.
Tài liệu tham khảo
Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, Takashi T, Takeda K, Akira S: Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med, 1998, 187, 1537–1542.
Chiba Y, Nakazawa S, Todoroki M, Shinozaki K, Sakai H, Misawa M: Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am J Respir Cell Mol Biol, 2009, 40, 159–167.
Chiba Y, Tanabe M, Goto K, Sakai H, Misawa M: Down-regulation of miR-133a contributes to up-regulation of RhoA in bronchial smooth muscle cells. Am J Respir Crit Care Med, 2009, 180, 713–719.
Chiba Y, Todoroki M, Nishida Y, Tanabe M, Misawa M: A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol, 2009, 41, 516–524.
Hershey GK: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol, 2003, 111, 677–690.
Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle F, Farrar WL: Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol, 1999, 65, 891–899.
Kumar N, Mishra J, Narang VS, Waters CM: Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin. J Biol Chem, 2007, 282, 30341–30345.
Kuperman D, Schofield B, Wills-Karp M, Grusby MJ: Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med, 1998, 187, 939–948.
Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ, Sheppard D: Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol, 2001, 25, 474–485.
Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S et al.: LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther, 2008, 7, 1176–1184.
Malaviya R, Zhu D, Dibirdik I, Uckun FM: Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem, 1999, 274, 27028–27038.
Malerba G, Pignatti PF: Areview of asthma genetics: gene expression studies and recent candidates. J Appl Genet, 2005, 46, 93–104.
McCusker CT, Wang Y, Shan J, Kinyanjui MW, Villeneuve A, Michael H, Fixman ED: Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J Immunol, 2007, 179, 2556–2564.
Moynihan BJ, Tolloczko B, El Bassam S, Ferraro P, Michoud MC, Martin JG, Laberge S: IFN-γ, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13. Respir Res, 2008, 9, Art. No. 84.
Sugimoto N, Nakahira M, Ahn HJ, Micallef M, Hamaoka T, Kurimoto M, Fujiwara H: Differential requirements for JAK2 and TYK2 in T cell proliferation and IFN-γ production induced by IL-12 alone or together with IL-18. Eur J Immunol, 2003, 33, 243–251.
Tanabe K, Nishimura K, Dohi S, Kozawa O: Mechanisms of interleukin-1β-induced GDNF release from rat glioma cells. Brain Res, 2009, 1274, 11–20.
Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, Cameron PM et al.: Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett, 2002, 12, 1219–1223.
Tibbles HE, Vassilev A, Wendorf H, Schonhoff D, Zhu D, Lorenz D, Waurzyniak B et al.: Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem, 2001, 276, 17815–17822.
Tomkinson A, Kanehiro A, Rabinovitch N, Joetham A, Cieslewicz G, Gelfand EW: The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by inter-leukin-5. Am J Respir Crit Care Med, 1999, 160, 1283–1291.
Tsuchiya Y, Takahashi N, Yoshizaki T, Tanno S, Ohhira M, Motomura W, Tanno S et al.: A Jak2 inhibitor, AG490, reverses lipin-1 suppression by TNF-α in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 2009, 382, 348–352.
Wills-Karp M: Interleukin-13 in asthma pathogenesis. Immunol Rev, 2004, 202, 175–190.